Repligen (RGEN) Tops Q1 EPS by 7c, Revenues Beat; Raises FY19 EPS/Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
May 9, 2019 7:30 AM EDTReports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growthRaises revenue guidance to $235-$241 million for full year 2019, representing 22%-25% organic growth Enters agreement to acquire analytics leader C TechnologiesCloses follow-on offering for net proceeds of $190 million
WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2019. Provided in this press release are financial highlights for the three-month period ended March 31, 2019, recent business... More
